Consensus is software that automates the product demo, and provides never before available visibility into the entire buying panel. With Consensus, prospective customers can get a personalized product demo, and share it with other stakeholders in the organization. Because closed sales now only require 1-2 live product demos, sale teams improve productivity by up to 3X, in addition to being provided with the analytics necessary to engage the entire buying panel in more a meaningful way, begin closing conversations sooner, and shorten the sales cycle. Check back for updates, original content, and opportunities to engage with this exciting new technology.

American Fork, US
Size (employees)
29 (est)+4%
Consensus was founded in 2013 and is headquartered in American Fork, US
Report incorrect company information

Consensus Office Locations

Consensus has an office in American Fork
American Fork, US (HQ)
c 782 S Auto Mall Dr
Show all (1)
Report incorrect company information

Consensus Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$7.1 m

Latest funding size

$4.20 m

Time since last funding

2 years ago


Consensus's latest funding round in April 2016 was reported to be $4.2 m. In total, Consensus has raised $7.1 m
Report incorrect company information

Consensus News and Updates

RBS teeters on edge of profits for first time in a decade

Investors will be on tenterhooks this week to see if Royal Bank of Scotland (RBS) has returned to profit for the first time after a decade in the cold, as Britain’s biggest banks report their full-year results. City analysts expect a net income loss of £984m, according to an average of estimates …

Tenement Maintenance: Consensus on issue; Difference in Approach

The Scottish Parliament debated tenement maintenance on Tuesday evening (9 January 2018), and whilst there was consensus that action is required to ensure the protection of Scotland’s historic and most common type of dwelling, there was a divergence in approach within the chamber

Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price

At a time when drugmakers—even rare disease drugmakers—routinely draw fire for their pricing decisions, Spark Therapeutics is surely prepping a pitch for its now-FDA-approved Luxturna. Analysts figure the pioneering therapy's retail price could break the $1 million barrier.

Lululemon Rallies After Dispelling Fears of an Athleisure Bubble

The yoga-pants maker topped analysts’ estimates with its third-quarter sales and profit, allaying fears that the athleisure market has lost a step.

Ralph Lauren's Retreat From Discounting Helps Bolster Profit

The brand's pursuit of higher-quality sales channels and fewer discounts helped second-quarter revenue reach $1.66 billion, just above the $1.64 billion predicted by analysts.

Does Everyone Need to Agree? How to Make Better, Faster Decisions According to an Expert

Getting everyone to agree usually leads to debates, delays, and disunity. Ditch the consensus and employ the 'golden vote' instead.
Show more
Report incorrect company information